FDA Flags J&J For Inadequate Oversight Of Consumer Devices
This article was originally published in The Tan Sheet
Executive Summary
FDA shifts its scrutiny of Johnson & Johnson’s OTC drug quality control onto the firm’s consumer devices, including K-Y moisturizers, after finding shortcomings in post-market monitoring and pre-market notification. The agency’s May 22 warning letter does not cite manufacturing issues.